31. Survival outcomes and prognostic factors of paclitaxel - carboplatin chemotherapy for the treatment of metastatic non-small cell lung cancer acquired resisted to first- and second-generations of EGFR tyrosine kinase inhibitors
Main Article Content
Abstract
This study aimed to evaluate survival outcomes and to analyze prognostic factors affected to median overall survival of paclitaxel - carboplatin chemotherapy for the treatment of advanced/ metastatic non-small cell lung cancer resisted to first- and second- generations of EGFR tyrosine kinase inhibitors without presence of T790M mutation at National Cancer Hospital from 01/2017 to 05/2022. This was a retrospective and prospective analysis of 55 patients with advanced/ metastatic metastatic non-small cell lung carcinoma were diagnosed and treated at National Cancer Hospital from 01/2017 to 05/2022. Our study showed that a mean progression-free survival (PFS) was 5.39 ± 2.2 months (range, 2 - 30 months), median PFS was 5.0 months. Mean overall survival (OS) was 17.4 ± 2.3 months and a median OS was 16.9 months. The 1-year and 2-year OS were 68.3% and 35.1%, respectively. The univariate analysis showed that ECOG and the mean PFS of TKIs treatment were risk factors significantly affected mean OS. Paclitaxel - carboplatin chemotherapy is one of regimen choices for patients with non-small cell lung cancer after acquired resistance to tyrosine kinase inhibitors without presence of T790M mutation with a mean overall survival (OS) of 17.4 ± 2.3 months and a median OS of 16.9 months
Article Details
Keywords
non-small cell lung cancer, advanced/ metastatic stage, Resistance to EGFR TKIs, paclitaxel-carboplatin
References
2. Davis F, Dolecek T, Mccarthy B, Villano J. Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. Neuro-Oncol. 2012;14:1171-1177.
3. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239-246.
4. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. N Engl J Med. 2009;361(10):947-957.
5. Sequist LV, Yang JCH, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma With EGFR Mutations. J Clin Oncol. 2013;31(27):3327-3334.
6. Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med. 2017;376(7):629-640.
7. Wu YL, Mok TSK, Han JY, et al. Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI). Ann Oncol. 2019;30:ix158.
8. Metro G, Chiari R, Mare M, et al. Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: A retrospective study with pharmacogenetic evaluation. Cancer Chemother Pharmacol. 2011;68(6):1405-1412.
9. Scagliotti GV. Pemetrexed plus carboplatin or oxaliplatin in advanced non-small cell lung cancer. Sel Proc Fromthe Chemother Found Symp Innov Cancer Ther Tomorrow. 2005;32:S5-S8.
10. Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: A cooperative multinational trial. Ann Oncol. 2002;13(10):1539-1549.
11. Sandler A, Gray R, Perry MC, et al. Paclitaxel-Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer. N Engl J Med. 2006;355(24):2542-2550.
12. El-Shenshawy HM, Taema S, El-Zahaf E, El-Beshbeshi W, Sharaf Eldeen D, Fathy A. Advanced non-small cell lung cancer in elderly patients: The standard every 3-weeks versus weekly paclitaxel with carboplatin. Egypt J Chest Dis Tuberc. 2012;61(4):485-493.